famotidine has been researched along with Kidney Diseases in 7 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The only risk factor for ranitidine was for patients who did not have their dosage corrected for renal function ("overdose"); these patients were twice as likely to experience a PADR compared with patients who received the correct dosage as determined by their renal function." | 1.29 | Risk for adverse events among patients receiving intravenous histamine2-receptor antagonists. ( Ben-Joseph, R; Russell, WL; Segal, R, 1993) |
| " Elimination half-life in the elderly patients with renal insufficiency was significantly prolonged compared to the elderly patients with normal renal function and the young volunteers." | 1.28 | Pharmacokinetics of famotidine in elderly patients with and without renal insufficiency and in healthy young volunteers. ( Fujiyama, S; Imai, Y; Inotsume, N; Matsui, H; Nakano, M; Nishimura, M; Sagara, K; Sato, T, 1989) |
| " The half-life of elimination was 2." | 1.27 | Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function. ( Hara, H; Hashimoto, N; Ishida, Y; Kawabata, M; Maekawa, M; Nakamura, S; Ohta, H; Takabatake, T; Ushiogi, Y; Yamamoto, Y, 1985) |
| " These data indicate that dosage adjustment may be necessary in patients who have renal insufficiency." | 1.27 | Disposition of famotidine in renal insufficiency. ( Abraham, PA; Chremos, AN; Halstenson, CE; Keane, WF; Matzke, GR; Opsahl, JA, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (71.43) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ben-Joseph, R | 1 |
| Segal, R | 1 |
| Russell, WL | 1 |
| Susanka, AL | 1 |
| Hancock, DL | 1 |
| Losson, M | 1 |
| Inotsume, N | 1 |
| Nishimura, M | 1 |
| Fujiyama, S | 1 |
| Sagara, K | 1 |
| Sato, T | 1 |
| Imai, Y | 1 |
| Matsui, H | 1 |
| Nakano, M | 1 |
| Ishigami, M | 1 |
| Sezai, Y | 1 |
| Shimada, Y | 1 |
| Maeda, T | 1 |
| Yabuki, S | 1 |
| Takabatake, T | 1 |
| Ohta, H | 1 |
| Maekawa, M | 1 |
| Yamamoto, Y | 1 |
| Ishida, Y | 1 |
| Hara, H | 1 |
| Nakamura, S | 1 |
| Ushiogi, Y | 1 |
| Kawabata, M | 1 |
| Hashimoto, N | 1 |
| Abraham, PA | 2 |
| Opsahl, JA | 2 |
| Halstenson, CE | 2 |
| Chremos, AN | 2 |
| Matzke, GR | 2 |
| Keane, WF | 2 |
7 other studies available for famotidine and Kidney Diseases
| Article | Year |
|---|---|
Risk for adverse events among patients receiving intravenous histamine2-receptor antagonists.
Topics: Age Factors; Cimetidine; Drug Interactions; Famotidine; Female; Humans; Injections, Intravenous; Kid | 1993 |
Staff pharmacist program for adjusting dosages on basis of creatinine clearance.
Topics: Anti-Infective Agents; Creatinine; Education, Pharmacy, Continuing; Famotidine; Humans; Kidney Disea | 1993 |
Pharmacokinetics of famotidine in elderly patients with and without renal insufficiency and in healthy young volunteers.
Topics: Adult; Aged; Aging; Famotidine; Female; Half-Life; Histamine H2 Antagonists; Humans; Intestinal Abso | 1989 |
Effects of famotidine, a new histamine H2-receptor antagonist, on renal function.
Topics: Acetylglucosaminidase; Adult; Aged; beta 2-Microglobulin; Blood Urea Nitrogen; Cimetidine; Creatinin | 1989 |
Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function.
Topics: Adult; Aged; Famotidine; Female; Histamine H2 Antagonists; Humans; Kidney; Kidney Diseases; Kinetics | 1985 |
The effect of famotidine on renal function in patients with renal insufficiency.
Topics: Adult; Creatinine; Famotidine; Female; Histamine H2 Antagonists; Humans; Kidney; Kidney Diseases; Ki | 1987 |
Disposition of famotidine in renal insufficiency.
Topics: Adult; Aged; Anti-Ulcer Agents; Creatinine; Famotidine; Female; Half-Life; Humans; Kidney Diseases; | 1987 |